경피적 기계적 혈전 제거 시스템 시장은 2025년에 20억 달러로 평가되었습니다. 2026년에는 21억 7,000만 달러에 이르고, CAGR 8.06%로 성장을 지속하여 2032년까지 34억 5,000만 달러에 달할 것으로 예측됩니다.
| 주요 시장 통계 | |
|---|---|
| 기준 연도 : 2025년 | 20억 달러 |
| 추정 연도 : 2026년 | 21억 7,000만 달러 |
| 예측 연도 : 2032년 | 34억 5,000만 달러 |
| CAGR(%) | 8.06% |
경피적 기계적 혈전제거술은 급성 및 만성 혈전성 질환에서 중요한 치료법으로 부상하고 있으며, 최소침습적 접근을 통해 신속한 혈전 제거를 가능하게 함으로써 임상 실무를 재구성하고 있습니다. 이 분야는 카테터 공학, 흡입 및 회전 메커니즘, 레이저 및 초음파 보조 장치, 이미지 유도 내비게이션 등의 발전을 활용하여 시술 성공률을 높이고 혈관 손상을 최소화하는 동시에 시술 성공률을 높이고 있습니다. 시술팀이 신속성과 안전성을 우선시하는 가운데, 혈전 포획성, 관강 보존성, 굴곡진 해부학적 구조에서의 전달성을 균형 있게 구현하기 위해 장치 설계가 진화하여 혈전 제거 기술이 다양한 혈관 부위에 적용될 수 있게 되었습니다.
기기 혁신, 임상적 근거, 의료서비스에 대한 기대가 결합되면서 경피적 기계적 혈전제거술의 전망은 변화하고 있습니다. 눈에 띄는 변화 중 하나는 적응증이 기존의 뇌혈관, 관상동맥 영역에서 말초혈관 및 복잡한 정맥 영역으로 확대되고 있다는 점이며, 여기서 장치의 적응성과 접근 전략이 매우 중요해졌습니다. 동시에, 시술의 효율성이 주요 차별화 요소로 작용하고 있으며, 설정 시간 단축, 빠른 혈전 포착 촉진, 기존 영상 진단 플랫폼과의 통합을 실현하는 시스템이 긴급한 환경에서 점점 더 중요시되고 있습니다.
미국발 관세 정책 변경은 경피적 기계적 혈전 제거 시스템의 세계 공급망, 조달 결정, 장비 비용 구조에 연쇄적인 영향을 미칠 것입니다. 부품 및 완제품에 대한 수입 관세가 상승하면 제조업체는 즉시 선택을 해야 합니다. 높은 투입비용을 흡수하거나, 구매자에게 전가하거나, 혹은 리스크 완화를 위해 공급망을 재구성하는 것입니다. 두 가지 옵션 모두 조달 주기, 병원과의 가격 협상, 기존 벤더와 신규 시장 진출기업 간경쟁 구도에 영향을 미칠 수 있습니다. 이에 따라 많은 제조업체들이 니어쇼어링을 추진하고 공급업체 기반을 다양화하여 단일 국가에 대한 의존도를 낮추고 생산 일정을 안정화시키고 있습니다.
제품 및 임상 전략에 대한 인사이트를 얻으려면 용도, 시스템 유형, 최종 사용 환경, 혈관 접근 방법 측면에서 디바이스가 어떻게 포지셔닝되어 있는지를 이해해야 합니다. 용도에 따라 경동맥 협착증에 초점을 맞춘 경동맥 중재시술, 비 ST상승형 심근경색증(Non-STEMI)과 ST상승형 심근경색증(STEMI)에 대한 관상동맥 시술, 허혈성 뇌졸중을 위한 신경혈관 치료, 심부정맥 혈전증 및 말초동맥 질환에 대한 말초 중재시술 등 다양한 치료 경로가 있습니다. 말초동맥질환에 대한 말초중재시술에 이르기까지 다양합니다. 이러한 다양한 용도는 뇌 순환 시술에서는 마이크로카테터의 조작성을 우선시하는 반면, 말초 중재시술에서는 대혈관 혈전 제거를 위한 견고성을 중시하는 등 서로 다른 기기 사양, 시술 워크플로우, 교육 수요를 창출합니다.
지역별 동향은 경피적 기계적 혈전제거 기술의 개발, 도입, 급여화 방식에 있어 매우 중요한 역할을 합니다. 북미와 남미에서는 잘 구축된 임상 네트워크와 높은 수준의 인터벤션 인프라 보급률로 인해 혁신적인 시스템의 빠른 도입이 이루어지고 있습니다. 한편, 상환 프레임워크와 병원의 조달 주기가 도입 시기와 규모에 영향을 미칩니다. 반면, 유럽, 중동 및 아프리카은 다양한 의료 모델을 포괄하고 있으며, 중앙집중식 조달과 국가 차원의 가이드라인이 일부 시장에서는 도입을 가속화하는 반면, 다른 시장에서는 도입 곡선이 길어지는 요인으로 작용하고 있습니다. 이 지역에서는 규제 조화와 국경을 초월한 임상적 협력이 중요한 촉진요인으로 작용합니다.
각 회사의 동향을 살펴보면 혈전 제거 시스템의 경쟁 환경을 정의하는 몇 가지 전략적 주제가 부각됩니다. 주요 의료기기 제조업체와 전문 분야의 혁신가들은 제품 개선, 임상적 근거 확대, 서비스 제공을 결합한 차별화 접근법을 추구하며 병원과의 관계를 강화하기 위해 노력하고 있습니다. 카테터 모양 개선과 흡입 효율 향상에 집중하여 시술 시간을 단축하고 첫 번째 성공률을 높이는 기업이 있는가 하면, 더 어려운 폐색에 대처하기 위해 기계적 작용과 에너지 기반 혈전 개질을 결합한 하이브리드 시스템에 투자하는 기업도 있습니다. 임상의를 위한 교육 프로그램 및 시뮬레이션 교육에 대한 전략적 투자는 도입 지원, 학습 곡선 단축, 의료 기관 전반의 광범위한 활용을 가능하게 하는 데 필수적입니다.
업계 리더은 기술 발전과 임상적 요구, 조달 현실을 일치시키기 위해 다음과 같은 실행 가능한 우선순위를 중심으로 전략을 수립해야 합니다. 첫째, 경동맥 협착증, 급성관상동맥증후군, 허혈성 뇌졸중, 심부정맥혈전증, 말초동맥질환 등 주요 적응증에서 디바이스 성능을 입증하는 다학제적 임상 증거에 투자하여 다양한 시술팀으로부터 신뢰성을 확보하는 것입니다. 다음으로, 제품의 모듈성과 상호운용성을 우선시하고, 기존 영상진단 플랫폼 및 지원 플랫폼과 원활하게 통합되어 도입 장벽을 낮춥니다. 셋째, 공급처를 적극적으로 다변화하고 현지 생산 및 현지 조립을 검토하여 관세 리스크를 줄이고 고객에 대한 리드 타임을 단축합니다.
이 분석의 기반이 되는 연구는 주요 이해관계자 인터뷰, 기기 수준의 기술 검토, 동료 평가 임상 연구 및 전문 학회 가이드라인에 대한 엄격한 평가를 통합한 것입니다. 주요 입력 정보로 인터벤션 의사, 병원 조달 책임자, 기기 기술자를 대상으로 구조화된 인터뷰를 실시하여 실제 임상에서의 시술 제약, 조달 고려사항, 성능에 대한 기대치를 파악했습니다. 이러한 관점을 임상 문헌의 체계적 검토와 통합하여 비교 안전성 프로파일, 첫 시술 성공률, 혈관 부위별 시술 워크플로우에 미치는 영향을 평가했습니다.
경피적 기계적 혈전제거술은 기기 혁신, 임상적 증거, 의료시스템의 우선순위가 교차하는 전략적 전환점에 서 있으며, 이것이 미래의 치료 경로를 결정하게 될 것입니다. 해부학적 적응 영역에 관계없이 보다 안전하고 신속하며 재현성 높은 시술의 실현에 중점을 두고 있으며, 고성능 메커니즘과 효율적인 워크플로우, 그리고 확고한 임상의 지원을 제공하는 솔루션이 성공을 거둘 수 있습니다. 다양한 의료 환경에서 지속 가능한 접근성 확보와 광범위한 보급을 위해서는 공급망 복원력, 규제 당국과의 협력, 지역 사정을 고려한 상업화 계획이 필수적입니다.
The Percutaneous Mechanical Thrombectomy System Market was valued at USD 2.00 billion in 2025 and is projected to grow to USD 2.17 billion in 2026, with a CAGR of 8.06%, reaching USD 3.45 billion by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 2.00 billion |
| Estimated Year [2026] | USD 2.17 billion |
| Forecast Year [2032] | USD 3.45 billion |
| CAGR (%) | 8.06% |
Percutaneous mechanical thrombectomy has emerged as a critical intervention across acute and chronic thrombotic conditions, reshaping clinical practice by enabling rapid clot removal with minimally invasive approaches. The field draws on advances in catheter engineering, aspiration and rotational mechanics, laser and ultrasonic adjuncts, and imaging-guided navigation to improve procedural success while minimising vessel trauma. As procedural teams prioritize speed and safety, device designs have evolved to balance clot engagement, lumen preservation, and deliverability through tortuous anatomy, making thrombectomy techniques applicable across a broad spectrum of vascular territories.
Contemporary practice demands integrated solutions that harmonize device performance with workflow efficiency, from pre-procedural imaging to post-procedural recovery. This imperative has driven cross-disciplinary collaboration among interventional cardiology, neurointerventional, vascular surgery, and interventional radiology communities. Consequently, evidence generation has focused on patient selection criteria, comparative safety profiles, and real-world procedural metrics, informing clinical guidelines and hospital adoption. Looking forward, ongoing refinements in materials science, catheter profiles, and adjunctive pharmacology are expected to enhance the therapeutic index of percutaneous mechanical thrombectomy and to expand its role within both acute stroke pathways and peripheral vascular interventions.
The landscape for percutaneous mechanical thrombectomy is undergoing transformative shifts as device innovation, clinical evidence, and care-delivery expectations converge. One prominent change is the broadening of indications beyond traditional cerebrovascular and coronary settings into peripheral and complex venous territories, where device adaptability and access strategies matter greatly. At the same time, procedural efficiency has become a primary differentiator; systems that reduce setup time, facilitate rapid clot engagement, and integrate with existing imaging platforms are increasingly favored in high-acuity environments.
Technological convergence is also notable. Hybrid designs that combine aspiration with mechanical fragmentation, or integrate ultrasonic energy to augment clot disruption, are redefining performance benchmarks. Alongside device evolution, payer and provider emphasis on value-based care is reshaping procurement decisions, prompting manufacturers to demonstrate not only clinical effectiveness but also downstream impact on length of stay, readmissions, and rehabilitation needs. Finally, the rise of modular ecosystems-where catheters, guidewires, and support platforms are designed for seamless compatibility-reflects a system-level shift toward interoperability, repeatable procedural workflows, and clinician-centric user experiences.
Tariff policy changes originating from the United States have a cascading influence on global supply chains, sourcing decisions, and device cost structures for percutaneous mechanical thrombectomy systems. When import duties increase on components or finished devices, manufacturers confront immediate choices: absorb higher input costs, pass them through to purchasers, or restructure supply chains to mitigate exposure. Each option carries implications for procurement cycles, pricing negotiations with hospitals, and the competitive landscape among established vendors and new entrants. In response, many manufacturers pursue nearshoring or diversify supplier bases to limit single-country dependencies and to stabilize production timelines.
Beyond direct input costs, tariff adjustments can affect the cadence of clinical trials and international regulatory filings when key components or system modules originate from affected regions. Delays in component availability may slow product iterations and limit the rollout of software-enabled upgrades that rely on integrated hardware. Healthcare providers can experience indirect impacts as procurement teams recalibrate capital equipment budgets, prioritizing devices with locally sourced components or longer service lifecycles. In combination, these dynamics encourage collaboration between manufacturers and hospital systems to structure long-term supply agreements, hedge against tariff volatility through contractual clauses, and invest in supply chain transparency. Such measures preserve access to critical thrombectomy devices while offering predictability for clinical programs and capital planning.
Insight into product and clinical strategy requires an understanding of how devices are positioned across applications, system types, end-use environments, and vascular access approaches. Based on application, therapeutic pathways span carotid artery interventions focused on carotid stenosis, coronary procedures addressing both Non-STEMI and STEMI presentations, neurovascular treatment specifically oriented to ischemic stroke, and peripheral interventions for deep vein thrombosis and peripheral arterial disease. This range of applications drives distinct device specifications, procedural workflows, and training demands, as cerebral circulation procedures prioritize microcatheter maneuverability while peripheral interventions emphasize robustness for large-vessel thrombus extraction.
Based on type, the technology landscape includes aspiration systems, laser systems, rotational systems, and ultrasonic systems, each offering different mechanisms for clot engagement and fragmentation. Device selection is influenced by thrombus composition, anatomical constraints, and procedural objectives, with aspiration systems often favored for soft thrombus and rotational or laser solutions considered for more organized occlusions. Based on end use, the mix of ambulatory surgical centers, clinics, and hospitals shapes procurement criteria; hospitals handle the highest-acuity cases and require integrated imaging and hybrid operating environments, whereas ambulatory and clinic settings prioritize rapid turnover and standardized procedural kits. Based on access, clinicians rely on brachial access, femoral access, and radial access depending on anatomical reach, complication profiles, and operator preference, and access strategy informs training, ancillary equipment needs, and post-procedural monitoring protocols.
Regional dynamics play a pivotal role in how percutaneous mechanical thrombectomy technologies are developed, adopted, and reimbursed. In the Americas, established clinical networks and a high prevalence of advanced interventional infrastructure favor rapid adoption of innovative systems, while reimbursement frameworks and hospital procurement cycles influence the timing and scale of deployments. In contrast, Europe, Middle East & Africa encompasses diverse healthcare models where centralized procurement and national-level guideline development can accelerate uptake in some markets while creating longer adoption curves in others; regulatory harmonization and cross-border clinical collaborations are important enablers in this region.
Asia-Pacific presents a mix of rapidly modernizing healthcare systems, large patient populations, and an expanding base of locally manufactured technologies that can compete on cost and bespoke design. Across all regions, differences in procedural volumes, clinician training pathways, and infrastructure maturity shape device preferences and support models. While global clinical evidence informs practice universally, regional reimbursement policies, referral patterns, and hospital capital planning introduce local variance in adoption trajectories and in the competitive strategies manufacturers pursue to gain traction.
A review of company activity highlights several strategic themes defining the competitive environment for thrombectomy systems. Leading medical device firms and specialist innovators are pursuing differentiated approaches that combine product refinement, expanded clinical evidence, and service offerings to deepen hospital relationships. Some companies concentrate on refining catheter geometry and aspiration efficiency to reduce procedure time and increase first-pass success rates, while others invest in hybrid systems that pair mechanical action with energy-based clot modification to address tougher occlusions. Strategic investments in clinician training programs and simulation-based education have become essential to support adoption, reducing learning curves and enabling broader use across institutional settings.
Mergers, acquisitions, and partnership models remain common as device manufacturers seek to augment portfolios with complementary technologies, software-enabled imaging integrations, and market access capabilities. Aftermarket services such as field-based technical support, warranty structures, and consumable management are increasingly central to commercial discussions, given hospitals' focus on predictable total cost of ownership. Finally, companies that provide clear evidence of device safety across multiple vascular territories and that demonstrate compatibility with common access strategies often secure stronger clinical endorsements, facilitating inclusion in care protocols and procurement frameworks.
Industry leaders should orient strategy around several actionable priorities that align technological progress with clinical needs and procurement realities. First, invest in cross-disciplinary clinical evidence that demonstrates device performance across the key application areas-carotid stenosis, coronary acute coronary syndromes, ischemic stroke, deep vein thrombosis, and peripheral arterial disease-to build credibility with diverse procedural teams. Second, prioritise product modularity and interoperability so devices integrate smoothly with prevailing imaging platforms and support platforms, thereby reducing adoption friction. Third, proactively diversify supply sources and consider localized manufacturing or assembly to mitigate tariff exposure and to shorten lead times for customers.
Equally important is the enhancement of clinician training and procedural simulation offerings to accelerate skill uptake and to reduce variability in outcomes. Commercially, adopting flexible pricing constructs, outcome-linked contracting, and bundled purchasing options can align vendor incentives with hospital priorities and support procurement approvals. Finally, engage with regulatory bodies and payer stakeholders early to clarify real-world evidence requirements and reimbursement pathways, ensuring that commercialization timelines reflect both clinical validation and reimbursement readiness.
The research underpinning this analysis synthesizes primary stakeholder interviews, device-level technical review, and a rigorous appraisal of peer-reviewed clinical studies and professional society guidance. Primary inputs included structured interviews with interventional clinicians, hospital procurement leaders, and device engineers to capture real-world procedural constraints, procurement considerations, and performance expectations. Those perspectives were integrated with a systematic review of clinical literature to assess comparative safety profiles, first-pass success narratives, and procedural workflow implications across vascular territories.
Complementing qualitative insights, a technical analysis of device architectures and mechanism-of-action classifications-aspiration, laser, rotational, and ultrasonic-provided a basis for evaluating suitability across thrombus types and access strategies. Supply chain and policy analyses examined component sourcing, tariff exposures, and manufacturing footprint considerations to surface resilience strategies. Throughout, findings were triangulated to ensure consistency between clinical imperatives, engineering constraints, and commercial realities, yielding conclusions that are directly actionable for device developers, hospital system leaders, and strategic investors.
Percutaneous mechanical thrombectomy stands at a strategic inflection point where device innovation, clinical evidence, and health system priorities intersect to determine future pathways of care. Across anatomical indications, the emphasis is on achieving safer, faster, and more reproducible procedures, and successful solutions will be those that reconcile high-performance mechanics with streamlined workflows and robust clinician support. Supply chain resilience, regulatory engagement, and regionally informed commercialization plans will be essential to sustain access and to enable widespread adoption across varied healthcare settings.
Ultimately, stakeholders who align product development with clinician needs, invest in rigorous evidence generation, and structure commercial models that address hospital fiscal constraints will be best positioned to influence care protocols and to capture long-term clinical endorsement. By focusing on modular design, interoperability, and comprehensive training programs, manufacturers can lower barriers to adoption and contribute meaningfully to improved patient outcomes across neurovascular, coronary, carotid, and peripheral vascular domains.